文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

潜在肾损伤暴露后急性肾损伤尿液细胞周期停滞标志物的动力学

Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论ICU患者常暴露于潜在肾损伤因素,尿[TIMP-2]•[IGFBP7]在暴露后24–48小时升高再回落,与AKI 2-3期匹配,但造影剂除外。

该研究为多中心SAPPHIRE研究的辅助分析,纳入北美和欧洲35个中心2010年9月至2012年6月收治的723例ICU成人患者,无干预。679例(94%)至少有一种、70%有一种以上、35%有三种及以上已知肾损伤暴露。截至研究第3天,累积暴露次数与AKI风险显著相关(p=0.02),但特定暴露类型与AKI无关联(p=0.22)。除造影剂外,五种暴露后发生AKI 2-3期的患者,尿[TIMP-2]•[IGFBP7]从暴露当天至24–48小时后有明显升高和回落;未发生AKI者该标志物无显著升高。

要点

  • 723例ICU成人中679例(94%)至少有一种潜在肾损伤暴露,70%有一种以上,35%有三种及以上。
  • 截至研究第3天累积暴露次数与AKI风险显著相关(p=0.02),特定暴露类型与AKI无关联(p=0.22)。
  • 除造影剂外,五种暴露后发生AKI 2-3期者,尿[TIMP-2]•[IGFBP7]从暴露当天至24–48小时后明显升高并回落。
  • 未发生AKI的患者尿[TIMP-2]•[IGFBP7]无显著升高。
  • 暴露于潜在肾损伤因素在ICU患者中常见,尿标志物动力学可与暴露时间对应解读。

适用人群与场景

  • ICU收治的危重成人患者,纳入723例。
  • 暴露因素包括大手术、静脉造影剂、万古霉素、非甾体抗炎药、哌拉西林/他唑巴坦。

诊断标准与关键阈值

  • AKI分期采用肾脏疾病改善全球结局(KDIGO)标准,分为2-3期、1期或无AKI。

研究设计与关键结果

  • 多中心辅助分析,35个中心,723例ICU成人,2010年9月至2012年6月,无干预。
  • 679例(94%)至少有一种暴露,70%有一种以上,35%有三种及以上。
  • 截至研究第3天累积暴露次数与AKI风险显著相关(p=0.02),特定暴露类型与AKI无关联(p=0.22)。
  • 除造影剂外,五种暴露后发生AKI 2-3期者,尿[TIMP-2]•[IGFBP7]从暴露当天至24–48小时后明显升高并回落;无AKI者无显著升高。

证据类型、等级与局限

  • 证据类型:多中心SAPPHIRE研究的辅助分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尿[TIMP-2]•[IGFBP7]动力学可与暴露时间对应解读,但造影剂暴露后不符合此规律。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 predict the development of acute kidney injury following renal insults of varied aetiology. To aid clinical interpretation, we describe the kinetics of biomarker elevations around an exposure.

DESIGN: In an ancillary analysis of the multicenter SAPPHIRE study, we examined the kinetics of the urinary [tissue inhibitor of metalloproteinase-2]•[insulin-like growth factor binding protein 7] in association with exposure to common renal insults (major surgery, IV radiocontrast, vancomycin, nonsteroidal anti-inflammatory drugs, and piperacillin/tazobactam).

SETTING: Thirty-five sites in North America and Europe between September 2010 and June 2012.

PATIENTS: Seven hundred twenty-three critically ill adult patients admitted to the ICU.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We compared the urinary [tissue metalloproteinase-2]•[insulin growth factor binding protein 7] kinetics from the day prior to exposure up to 5 days after exposure in patients developing acute kidney injury stage 2-3, stage 1, or no acute kidney injury by Kidney Disease Improving Global Outcome criteria. Among the 723 patients, 679 (94%) had at least one, 70% had more than one, and 35% had three or more exposures to a known renal insult. There was a significant association between cumulative number of exposures up to study day 3 and risk of acute kidney injury (p = 0.02) but no association between the specific type of exposure and acute kidney injury (p = 0.22). With the exception of radiocontrast, patients who developed acute kidney injury stage 2-3 after one of the five exposures, had a clear rise and fall of urinary [tissue inhibitor of metalloproteinase-2]•[insulin-like growth factor binding protein 7] from the day of exposure to 24-48 hours later. In patients without acute kidney injury, there was no significant elevation in urinary [tissue inhibitor of metalloproteinase-2]•[insulin-like growth factor binding protein 7].

CONCLUSIONS: Exposure to potential renal insults is common. In patients developing acute kidney injury stage 2-3, the kinetics of urinary [tissue inhibitor of metalloproteinase-2]•[insulin-like growth factor binding protein 7] matched the exposure except in the case of radiocontrast.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Ostermann M, McCullough PA, Forni LG, et al. Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults. Crit Care Med. 2018. PMID: 29189343. doi:10.1097/CCM.0000000000002847

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。